Skip to main content
TipRanks
Go Ultimate75% OFF

Holista Colltech Limited (HCT) AI Stock Analysis

2 Followers
AU:HCT

Holista Colltech Limited

(ASX:HCT)

Select Model
Rating:39Underperform
Price Target:AUD 0.03â–¼(-5.88% Downside)
Action:reiterated
Date:11/20/26

The score is weighed down primarily by weak financial performance (revenue contraction, deeper losses, and sustained negative free cash flow indicating funding risk). Technical indicators also point to a bearish trend with strong downside momentum. Valuation provides limited support due to negative earnings and no dividend yield.

Positive Factors
Nutraceutical Business ModelA focus on natural-health products, collagen ingredients, and nutraceutical formulations gives HCT exposure to multiple wellness applications. The model can serve both consumer products and industrial customers, creating opportunities to monetize product development across finished goods and ingredient sales over time.
Negative Factors
Revenue and Profitability DeteriorationSharp revenue contraction combined with a materially deeper net loss points to weak operating momentum and limited earnings quality. This deterioration can reduce the company’s ability to fund product development internally, weaken commercial execution, and make recovery dependent on a sustained improvement in demand and margins.

Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)

-80%-60%-40%-20%0%20%40%AU:HCT-62.22%EWA+8.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 12.51M
Dividend Yield
―
Average Volume (3M)
29.23K
Price to Earnings (P/E)
-3.9
Beta (1Y)
0.48
Revenue Growth
0.72%
EPS Growth
-486.96%
Country
Australia
Employees
3
Sector
Consumer Defensive
Sector Strength
62
Industry
Biotechnology

Holista Colltech Limited Business Overview & Revenue Model

Company Description

Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food In...

How the Company Makes Money

HCT’s core revenue model is centered on monetizing proprietary or in-house developed health and nutraceutical products and ingredients. The company makes money primarily through (1) sales of finished products (e.g., branded or private-label nutraceut...

Holista Colltech Limited Financial Statement Overview

Summary

Financials indicate significant strain: revenue contracted sharply in the latest period, profitability worsened into a deeper net loss, and cash burn remains persistent with negative operating and free cash flow. While equity returned to positive in 2025, leverage remains high relative to equity, leaving elevated funding and execution risk.

Income Statement

24Negative

Balance Sheet

38Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.87M5.76M5.60M5.95M8.24M8.02M
Gross Profit1.16M770.25K87.03K370.06K4.24M1.31M
EBITDA-489.16K-788.46K304.37K-4.52M-1.02M-957.40K
Net Income-3.22M-948.92K-84.21K-4.81M-1.45M-1.26M
Balance Sheet
Total Assets3.72M5.87M3.34M3.35M5.52M6.93M
Cash, Cash Equivalents and Short-Term Investments564.56K2.16M21.72K59.77K117.53K1.21M
Total Debt1.32M1.59M1.77M1.57M1.22M890.32K
Total Liabilities6.70M6.29M6.71M6.74M3.96M3.95M
Stockholders Equity-1.48M1.12M-1.73M-1.97M2.83M4.10M
Cash Flow
Free Cash Flow-1.45M-1.52M-1.02M-411.67K-1.19M-1.72M
Operating Cash Flow-1.28M-1.35M-1.01M-407.12K-1.11M-1.68M
Investing Cash Flow-29.88K-176.36K692.12K-46.70K-105.69K50.35K
Financing Cash Flow1.86M3.65M143.75K418.42K120.85K109.49K

Holista Colltech Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.03

Price Trends

50DMA0.04Negative
100DMA0.05Negative
200DMA0.06Negative

Market Momentum

MACD-0.00Negative
RSI22.18Positive
STOCH-11.54Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 22.18 is Positive, neither overbought nor oversold. The STOCH value of -11.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HCT.

Holista Colltech Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

AU:HCT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:BLSAU:BLS84OutperformAUD 195.94M23.0956.29%―160.87%188.14%
AU:CLVAU:CLV76OutperformAUD 200.40M18.3713.83%1.96%13.26%49.05%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
AU:NOUAU:NOU49NeutralAUD 34.64M-0.5313.40%―8.82%55.22%
AU:BUBAU:BUB48NeutralAUD 66.24M-13.65-11.08%―9.08%-183.87%
AU:NGSAU:NGS46NeutralAUD 18.32M-0.01-130.72%―-33.05%94.22%
AU:HCTAU:HCT39UnderperformAUD 12.51M-3.911795.70%―0.72%-486.96%

* Consumer Defensive Sector Average

Performance Comparison

0%100%200%AU:HCTAU:NOUAU:BLSAU:BUBAU:NGSAU:CLVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:HCT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:HCTHolista Colltech Limited0.03-0.05-60.00%
AU:NOUNoumi Limited0.130.014.17%
AU:BLSBioxyne Limited0.830.46124.32%
AU:BUBBubs Australia Ltd.0.07-0.07-49.29%
AU:NGSNutritional Growth Solutions Ltd.0.02-0.00-17.39%
AU:CLVClover Corporation Limited1.150.3543.57%

Holista Colltech Limited Corporate Events

Holista Colltech Lifts Margins, Books One-Off Loss as ProImmune Dispute Settled

Aug 31, 2026

Holista Colltech reported a 3.6% rise in group revenue to $2.99 million for the half year to June 2026, with gross margin improving to 44.3% on a better sales mix and cost control. The dietary supplements division drove performance with 12.2% sales g...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026